BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)
LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation
Sponsor: Array BioPharma
This PHASE2 trial investigates Patients With BRAFV600 E or BRAFV600K Mutation and Relapsed or Refractory Multiple Myeloma and is currently completed. Array BioPharma leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2020 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Array BioPharma
- Coordinating Centre for Clinical Trials Heidelberg
- German Cancer Research Center
- University Hospital Heidelberg
- University of Heidelberg Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .